Clinical trial
Rapamycin in Relapsed Acute Lymphoblastic Leukemia
NCT00874562 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Rapamycin in Relapsed Acute Lymphoblastic Leukemia
- Lead sponsor
- Dana-Farber Cancer Institute
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 31, 2007
- Completion date
- April 30, 2016
- Enrollment
- 6 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute lymphoblastic leukemia